Trametinib is useless after taking it for one year. Is it drug resistance?

Trametinib(trametinib) is an inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK2 in cells harboring b-Raf serine-threonine kinase (BRAF) V600E or V600K mutations. It has remarkable anti-tumor effect.

Resistance can develop to all targeted drugs, including trametinib. Trametinib has no effect after taking it for one year, which may be due to the development of drug resistance. Patients should be reviewed on time during the period of taking it or if adverse reactions occur and they should seek medical treatment in time. Once drug resistance develops, they should inform the doctor immediately and discontinue the drug or change the treatment plan according to the doctor's advice.

The most common side effects of trametinib (which may affect more than 1 in 5 people) are rash, diarrhea, fatigue, peripheral edema (swelling, especially in the ankles and feet), nausea, and dermatitis acneiformis (acne-like inflammation of the skin). When trametinib is used with dabrafenib, the most common side effects (which may affect more than 1 in 5 people) are fever, fatigue, nausea, chills, headache, diarrhea, vomiting, joint pain, and rash. The European Medicines Agency decided that trametinib's benefits for cancers carrying the BRAF V600 mutation outweigh its risks and that it can be authorized for use in the EU. The agency believes that trametinib shows clinically relevant benefit when used alone or in combination with dabrafenib in patients with non-small cell lung cancer or melanoma that has spread or is unresectable.该机构还发现它对已经手术切除的晚期黑色素瘤患者有益。 With appropriate measures, the side effects of Mekinist are considered acceptable and controllable. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.